Trial result ·
Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This trial tested methotrexate in people with polymyalgia rheumatica (PMR). All had been found to have PMR only a short time before. They had used glucocorticoid (GC) drugs for under 8 weeks. People were put by chance into a methotrexate group or a dummy drug group. The methotrexate dose was 25 mg each week. Neither the people nor their doctors knew who got which. Everyone also cut down their GC dose over 24 weeks. The trial lasted 52 weeks.
What they found
The main goal was checked at week 52. To reach it, people had to score under 10 on a PMR activity scale. They also had to be off GC drugs. In the end, 58 people were counted in the results. More people in the methotrexate group reached this goal than in the dummy group. The team reports this gap was statistically significant.
What it means for patients
The team says methotrexate at 25 mg each week raised the chance of this goal. This was in people who had just found out they had PMR. The team says the results show a gain from starting methotrexate early. Past trials used lower doses and gave mixed results.
Why it is not certain yet
The team calls this trial small. Only 58 people were counted in the results. Follow-up ended at 52 weeks. The team says more work is needed on when to start methotrexate. The abstract does not report side effects.
Source
Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica.
PubMed · PMID 41423373We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Polymyalgia rheumatica publications